Clinical trial

AMTEC IIT: Phase 2 Multiarm Study in TNBC

NCT03801369

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-12-12

PhasePHASE2

Study timeline

Study start (actual)2018-12-12Date precision: day

Registry last updated2026-02-25

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Anatomic Stage IV Breast Cancer AJCC v8unresolved

Metastatic Triple-Negative Breast Carcinomaunresolved

Interventions

BiopsyPROCEDURE

CapivasertibDRUG · verified · RxNorm: capivasertib

CeralasertibDRUG

DurvalumabBIOLOGICAL

OlaparibDRUG · verified · RxNorm: olaparib

Quality-of-Life AssessmentOTHER

SelumetinibDRUG · verified · RxNorm: selumetinib

Sponsors & collaborators

Gordon Mills, MD, PhDlead sponsor

AstraZenecacollaborator

Oregon Health and Science Universitycollaborator

Mapped research locations

PortlandOregon, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03801369 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.